Details of Disease

General Information of Disease (ID: DIS5S9R7)

Disease Name Neovascular age-related macular degeneration
Synonyms
Kuhnt-Junius degeneration; wet ARMD; wet AMD; Senile macular degeneration, wet; wet age related macular degeneration; exudative senile macular degeneration of retina; neovascular age-related macular degeneration; wet senile macular retinal degeneration
Disease Class 9B71: Retinopathy
Definition
A form of RETINAL degeneration in which abnormal CHOROIDAL NEOVASCULARIZATION occurs under the RETINA and MACULA LUTEA, causing bleeding and leaking of fluid. This leads to bulging and or lifting of the macula and the distortion or destruction of central vision.
Disease Hierarchy
DIS0XS2C: Age-related macular degeneration
DIS5S9R7: Neovascular age-related macular degeneration
ICD Code
ICD-11
ICD-11: 9B78.3Z
ICD-9
ICD-9: 362.5
Expand ICD-11
'9B78.3Z
Expand ICD-9
362.5
Disease Identifiers
MONDO ID
MONDO_0005417
MESH ID
D057135
UMLS CUI
C2237660
MedGen ID
389185

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 2 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Faricimab DM83SEB Approved Antibody [1]
Pegaptanib DMOWEBU Approved Aptamer [2]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 6 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
ABP 938 DM00ACQ Phase 3 Fusion protein [3]
RG7716 DMKDHU2 Phase 3 Small molecular drug [4]
SB15 DMTOS6C Phase 3 Monoclonal antibody [5]
REGN910-3 DMTBRPO Phase 2 Antibody [6]
Sirna-027 DMZTQD8 Phase 1/2 siRNA drug [7]
Zifibancimig DMIJ2MZ Phase 1 NA [8]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 14 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
ABCA1 TTJW1GN Strong Genetic Variation [9]
AMD1 TTBFROQ Strong Biomarker [10]
C3 TTJGY7A Strong Genetic Variation [9]
CETP TTFQAYR Strong Genetic Variation [9]
CFB TTA0P7K Strong Genetic Variation [11]
CFH TTUW6OP Strong Genetic Variation [12]
CFI TT6ATLX Strong Genetic Variation [9]
CYP21A2 TTP4GLG Strong Genetic Variation [9]
HTRA1 TT8POQR Strong Genetic Variation [13]
KCNT2 TTLU5FO Strong Genetic Variation [9]
SLC44A4 TT0NYDG Strong Genetic Variation [14]
SRPK2 TTCZEJ9 Strong Genetic Variation [9]
TMEM97 TT9NXW4 Strong Genetic Variation [9]
TRPM3 TTO3TD8 Strong Genetic Variation [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 DTT(s)
This Disease Is Related to 1 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC16A8 DT39AOM Strong Genetic Variation [9]
------------------------------------------------------------------------------------
This Disease Is Related to 2 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
ALDH1A2 DEKN1H4 Strong Genetic Variation [9]
RDH5 DESI4OK Strong Genetic Variation [9]
------------------------------------------------------------------------------------
This Disease Is Related to 23 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ACAD10 OTFAG3M0 Strong Genetic Variation [9]
ARHGAP21 OT6XY8Y9 Strong Genetic Variation [9]
ARMS2 OTUXHJ9H Strong Genetic Variation [12]
B3GLCT OTXH6KOQ Strong Genetic Variation [9]
C2 OTHMF4YM Strong Genetic Variation [11]
C9 OT7I5FDX Strong Genetic Variation [9]
CFHR5 OT7BMOYE Strong Genetic Variation [9]
CNN2 OTH3CSXA Strong Genetic Variation [9]
COL4A3 OT6SB8X5 Strong Genetic Variation [9]
COL8A1 OTWBTED2 Strong Genetic Variation [9]
EXOC5 OT9S9NJ7 Strong Genetic Variation [15]
FGD6 OTI0T62C Strong Biomarker [16]
FUT6 OTBZUQ7F Strong Genetic Variation [9]
LHFPL6 OTY6LHJY Strong Genetic Variation [13]
LIPC OTZY5SC9 Strong Genetic Variation [9]
MARK4 OT6Z2TGV Strong Genetic Variation [9]
NPLOC4 OTC1WUVF Strong Genetic Variation [9]
PBX2 OTEBYCAW Strong Genetic Variation [9]
PILRA OTBE0PLF Strong Genetic Variation [9]
RAD51B OTCJVRMY Strong Genetic Variation [9]
STK19 OTYM6437 Strong Genetic Variation [9]
SYN3 OTSGYNA5 Strong Genetic Variation [9]
TNR OTVJGAFN Strong Genetic Variation [17]
------------------------------------------------------------------------------------
⏷ Show the Full List of 23 DOT(s)

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761235.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6836).
3 ClinicalTrials.gov (NCT04270747) A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea?) in Subjects With Neovascular Age-related Macular Degeneration. U.S.National Institutes of Health.
4 ClinicalTrials.gov (NCT04777201) A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (AVONELLE-X). U.S. National Institutes of Health.
5 ClinicalTrials.gov (NCT04450329) A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB15 (Proposed Aflibercept Biosimilar) and Eylea? in Subjects With Neovascular Age-related Macular Degeneration. U.S.National Institutes of Health.
6 ClinicalTrials.gov (NCT02713204) Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX). U.S. National Institutes of Health.
7 2011 Pipeline of Sirna Therapeutics.
8 ClinicalTrials.gov (NCT04567303) A Three-Part, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Zifibancimig Following Intravitreal Administration of Multiple Ascending Doses and Continuous Delivery From the Port Delivery in Patients With Neovascular Age-Related Macular Degeneration. U.S.National Institutes of Health.
9 A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants.Nat Genet. 2016 Feb;48(2):134-43. doi: 10.1038/ng.3448. Epub 2015 Dec 21.
10 Appointment Compliance in Patients With Diabetic Macular Edema and Exudative Macular Degeneration.Ophthalmic Surg Lasers Imaging Retina. 2018 Mar 1;49(3):186-190. doi: 10.3928/23258160-20180221-06.
11 Heritability and genome-wide association study to assess genetic differences between advanced age-related macular degeneration subtypes.Ophthalmology. 2012 Sep;119(9):1874-85. doi: 10.1016/j.ophtha.2012.03.014. Epub 2012 Jun 15.
12 Genome-wide association study of neovascular age-related macular degeneration in the Thai population.J Hum Genet. 2017 Nov;62(11):957-962. doi: 10.1038/jhg.2017.72. Epub 2017 Jul 13.
13 A genome-wide association study identified a novel genetic loci STON1-GTF2A1L/LHCGR/FSHR for bilaterality of neovascular age-related macular degeneration.Sci Rep. 2017 Aug 3;7(1):7173. doi: 10.1038/s41598-017-07526-9.
14 New loci and coding variants confer risk for age-related macular degeneration in East Asians.Nat Commun. 2015 Jan 28;6:6063. doi: 10.1038/ncomms7063.
15 Genome-wide association study suggests four variants influencing outcomes with ranibizumab therapy in exudative age-related macular degeneration.J Hum Genet. 2018 Oct;63(10):1083-1091. doi: 10.1038/s10038-018-0493-0. Epub 2018 Jul 27.
16 A missense variant in FGD6 confers increased risk of polypoidal choroidal vasculopathy.Nat Genet. 2016 Jun;48(6):640-7. doi: 10.1038/ng.3546. Epub 2016 Apr 18.
17 Genome-wide analysis of disease progression in age-related macular degeneration.Hum Mol Genet. 2018 Mar 1;27(5):929-940. doi: 10.1093/hmg/ddy002.